Computational Analysis of Potential Inhibitors Selected Based On Structural Similarity for the Src SH2 Domain

Authors: W. P. Hu, J. V. Kumar, Jeffrey J. P. Tsai

Abstract:

The inhibition of SH2 domain regulated protein-protein interactions is an attractive target for developing an effective chemotherapeutic approach in the treatment of disease. Molecular simulation is a useful tool for developing new drugs and for studying molecular recognition. In this study, we searched potential drug compounds for the inhibition of SH2 domain by performing structural similarity search in PubChem Compound Database. A total of 37 compounds were screened from the database, and then we used the LibDock docking program to evaluate the inhibition effect. The best three compounds (AP22408, CID 71463546 and CID 9917321) were chosen for MD simulations after the LibDock docking. Our results show that the compound CID 9917321 can produce a more stable protein-ligand complex compared to other two currently known inhibitors of Src SH2 domain. The compound CID 9917321 may be useful for the inhibition of SH2 domain based on these computational results. Subsequently experiments are needed to verify the effect of compound CID 9917321 on the SH2 domain in the future studies.

Keywords: Nonpeptide inhibitor, Src SH2 domain, LibDock, molecular dynamics simulation.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1093448

References:

I. Sadowski, J. C. Stone, and T. Pawson, "A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps," Mol. Cell Biol., vol. 6, pp. 4396-4408, Dec. 1986.
[2] T. K. Sawyer, "Src homology-2 domains: structure, mechanisms, and drug discovery," Biopolymers, vol. 47, pp. 243-261, Dec. 1998.
[3] M. Matsuda, B. J. Mayer, and H. Hanafusa, "Identification of domains of the v-crk oncogene product sufficient for association with phosphotyrosine-containing proteins," Mol. Cell. Biol., vol. 11, pp. 1607-1613, Mar. 1991.
[4] B. J. Mayer, P. K. Jackson, and D. Baltimore, "The noncatalyticsrc homology region 2 segment of abl tyrosine kinase binds to tyrosine-phosphorylated cellular proteins with high affinity," Proc. Natl. Acad. Sci. U S A, vol. 88, pp. 627-631, Jan. 15 1991.
[5] P. Morlacchi, P. K. Mandal, and J. S. McMurray, "Synthesis and in vitro evaluation of a peptidomimetic inhibitor targeting the Src homology 2 (SH2) domain of STAT6," ACS Med. Chem. Lett., vol. 5, pp. 69-72, Jan. 2013.
[6] Y. Q. Duan, Y. Ma, X. J. Wang, Y. Y. Ji, R. L. Wang, W. L. Dong, et al., "Design Potential Selective Inhibitors for Treating Cancer by Targeting the Src Homology 2 (SH2) Domain-Containing Phosphatase 2 (Shp2) with Core Hopping Approach," Protein Pept. Lett.,Epub ahead of print.
[7] Z. Songyang, S. E. Shoelson, M. Chaudhuri, G. Gish, T. Pawson, W. G. Haser, et al., "SH2 domains recognize specific phosphopeptide sequences," Cell, vol. 72, pp. 767-778, Mar. 1993.
[8] D. A. Henriques and J. E. Ladbury, "Inhibitors to the Src SH2 domain: a lesson in structure--thermodynamic correlation in drug design," Arch. Biochem. Biophys., vol. 390, pp. 158-168, Jun. 2001.
[9] W. Shakespeare, M. Yang, R. Bohacek, F. Cerasoli, K. Stebbins, R. Sundaramoorthi, et al., "Structure-based design of an osteoclast-selective, nonpeptidesrc homology 2 inhibitor with in vivoantiresorptive activity," Proc. Natl. Acad. Sci. U S A, vol. 97, pp. 9373-9378, Aug. 2000.
[10] A. Shahripour, M. S. Plummer, E. A. Lunney, K. S. Para, C. J. Stankovic, J. R. Rubin, et al., "Novel phosphotyrosinemimetics in the design of peptide ligands for pp60src SH2 domain," Bioorg. Med. Chem. Lett., vol. 6, pp. 1209-1214, Apr. 1996.
[11] F. A. Al-Obeidi and K. S. Lam, "Development of inhibitors for protein tyrosine kinases," Oncogene, vol. 19, pp. 5690-5701, Nov. 2000.